Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Faivre

Showing results (251-260 of 361) with videos related to

Pageof 37
Sort By:
Gut|January 14, 2005
Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgeryL Ciccolallo, R Capocaccia, M P Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2003
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentaryM Sant, T Aareleid, F Berrino, et al.
Molecular Cancer Therapeutics|May 5, 2017
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsLloyd T Lam, Xiaoyu Lin, Emily J Faivre, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2006
Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM)N Bossard, M Velten, L Remontet, et al.
Revue D'Epidemiologie Et De Sante Publique|April 10, 2003
Cancer incidence and mortality in France over the period 1978-2000L Remontet, J Estève, A-M Bouvier, et al.
Cancer Research|April 19, 2017
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic StrategiesMai H Bui, Xiaoyu Lin, Daniel H Albert, et al.
Revue D'Epidemiologie Et De Sante Publique|June 13, 2008
Cancer incidence and mortality in France over the period 1980-2005A Belot, P Grosclaude, N Bossard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2003
European health systems and cancer careA Micheli, J W Coebergh, E Mugno, et al.
Molecular Cancer Therapeutics|July 13, 2021
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Tianyu Cai, Xiaoyu Lin, et al.
Journal of Medicinal Chemistry|September 27, 2017
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain InhibitorKeith F McDaniel, Le Wang, Todd Soltwedel, et al.
Pageof 37

Showing results (251-260 of 361) with videos related to

Sort By:
Pageof 37
Gut|January 14, 2005
Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgeryL Ciccolallo, R Capocaccia, M P Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2003
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentaryM Sant, T Aareleid, F Berrino, et al.
Molecular Cancer Therapeutics|May 5, 2017
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsLloyd T Lam, Xiaoyu Lin, Emily J Faivre, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2006
Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM)N Bossard, M Velten, L Remontet, et al.
Revue D'Epidemiologie Et De Sante Publique|April 10, 2003
Cancer incidence and mortality in France over the period 1978-2000L Remontet, J Estève, A-M Bouvier, et al.
Cancer Research|April 19, 2017
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic StrategiesMai H Bui, Xiaoyu Lin, Daniel H Albert, et al.
Revue D'Epidemiologie Et De Sante Publique|June 13, 2008
Cancer incidence and mortality in France over the period 1980-2005A Belot, P Grosclaude, N Bossard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2003
European health systems and cancer careA Micheli, J W Coebergh, E Mugno, et al.
Molecular Cancer Therapeutics|July 13, 2021
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Tianyu Cai, Xiaoyu Lin, et al.
Journal of Medicinal Chemistry|September 27, 2017
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain InhibitorKeith F McDaniel, Le Wang, Todd Soltwedel, et al.
Pageof 37